Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma (NCT03628209)

🧪 Interventions in This Study

• Nivolumab (DRUG)
• Azacitidine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (22 Sites)

• University of Alabama at Birmingham — Birmingham, Alabama
• Children's Hospital of Los Angeles, USC Norris Comprehensive Cancer Center — Los Angeles, California
• Children's Hospital of Colorado — Aurora, Colorado
• Connecticut Children's Medical Center — Hartford, Connecticut
• Alfred I DuPont Hospital for Children — Wilmington, Delaware
• Shand's Hospital for Children at the University of Florida — Gainesville, Florida
• Nemours Children's Hospital — Jacksonville, Florida
• University of Miami - Sylvester Comprehensive Cancer Center — Miami, Florida
• Nemours Children's Clinic — Orlando, Florida
• Johns Hopkins All Children's Hospital — St. Petersburg, Florida
• H. Lee Moffitt Cancer Center and Research Institute, Coordinating Center — Tampa, Florida
• University of Kentucky, Markey Cancer Center — Lexington, Kentucky
• Johns Hopkins University, Sidney Kimmel Cancer Center — Baltimore, Maryland
• Roswell Park Comprehensive Cancer Center — Buffalo, New York
• University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
• Carolina Medical Center, Levine Cancer Institute — Charlotte, North Carolina
• Duke Health — Durham, North Carolina
• Cleveland Clinic — Cleveland, Ohio
• Nationwide Children's Hospital — Columbus, Ohio
• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
• University of Texas Southwestern Medical Center — Dallas, Texas
• University of Texas M.D. Anderson Cancer Center — Houston, Texas

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Osteosarcoma

• Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors — New York, New York
• SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma — Los Angeles, California
• Olaparib With Ceralasertib in Recurrent Osteosarcoma — San Francisco, California
• A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma — Seattle, Washington
• iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma — Houston, Texas

Explore by condition: All Osteosarcoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.